Assessment of fracture risk and its application to screening for postmenopausal osteoporosis, Report of a WHO Study Group. World Health Organ Tech. Rep. Ser. 843, 1–129 (1994)

Google Scholar 

H. Sun, P. Saeedi, S. Karuranga, M. Pinkepank, K. Ogurtsova, B.B. Duncan et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diab. Res Clin. Pr. 183, 109119 (2022)

Article  Google Scholar 

L.D. Mastrandrea, J. Wactawski-Wende, R.P. Donahue, K.M. Hovey, A. Clark, T. Quattrin, Young women with type 1 diabetes have lower bone mineral density that persists over time. Diab. Care 31(9), 1729–1735 (2008)

Article  Google Scholar 

B. Lecka-Czernik, Bone as a target of type 2 diabetes treatment. Curr. Opin. Investig. Drugs 10(10), 1085–1090 (2009)

PubMed  CAS  Google Scholar 

L.C. Hofbauer, B. Busse, R. Eastell, S. Ferrari, M. Frost, R. Müller et al. Bone fragility in diabetes: novel concepts and clinical implications. Lancet Diab. Endocrinol. 10(3), 207–220 (2022)

Article  Google Scholar 

A. Sheu, J.R. Greenfield, C.P. White, J.R. Center, Assessment and treatment of osteoporosis and fractures in type 2 diabetes. Trends Endocrinol. Metab. 33(5), 333–344 (2022)

Article  PubMed  CAS  Google Scholar 

H. Wang, Y. Ba, Q. Xing, J.-L. Du, Diabetes mellitus and the risk of fractures at specific sites: a meta-analysis. BMJ Open 9(1), e024067 (2019)

Article  PubMed  PubMed Central  Google Scholar 

N.H. Rasmussen, J. Dal, F. de Vries, J.P. van den Bergh, M.H. Jensen, P. Vestergaard, Diabetes and fractures: new evidence of atypical femoral fractures? Osteoporos. Int 31(3), 447–455 (2020)

Article  PubMed  CAS  Google Scholar 

N. Napoli, M. Chandran, D.D. Pierroz, B. Abrahamsen, A.V. Schwartz, S.L. Ferrari, Mechanisms of diabetes mellitus-induced bone fragility. Nat. Rev. Endocrinol. 13(4), 208–219 (2017)

Article  PubMed  CAS  Google Scholar 

T.E. LaMoia, G.I. Shulman, Cellular and molecular mechanisms of metformin action. Endocr. Rev. 42(1), 77–96 (2021)

Article  PubMed  Google Scholar 

A.M. Cortizo, C. Sedlinsky, A.D. McCarthy, A. Blanco, L. Schurman, Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture. Eur. J. Pharm. 536(1–2), 38–46 (2006)

Article  CAS  Google Scholar 

I. Kanazawa, T. Yamaguchi, S. Yano, M. Yamauchi, T. Sugimoto, Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem Biophys. Res Commun. 375(3), 414–419 (2008)

Article  PubMed  CAS  Google Scholar 

L. Schurman, A. McCarthy, C. Sedlinsky, M. Gangoiti, V. Arnol, L. Bruzzone et al. Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells. Exp. Clin. Endocrinol. Diab. 116(06), 333–340 (2008)

Article  CAS  Google Scholar 

T.J. de Vries, A.S. Kleemann, J. Jin, T. Schoenmaker, The differential effect of metformin on osteocytes, osteoblasts, and osteoclasts. Curr. Osteoporos. Rep. 21(6), 743–749 (2023)

Article  PubMed  PubMed Central  Google Scholar 

M. Khorraminejad-Shirazi, M. Sani, T. Talaei-Khozani, M. Dorvash, M. Mirzaei, M.A. Faghihi et al. AICAR and nicotinamide treatment synergistically augment the proliferation and attenuate senescence-associated changes in mesenchymal stromal cells. Stem Cell Res. Ther. 11(1), 45 (2020)

Article  PubMed  PubMed Central  CAS  Google Scholar 

J.J. Patel, O.R. Butters, T.R. Arnett, PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity. Cell Biochem. Funct. 32(4), 368–377 (2014)

Article  PubMed  CAS  Google Scholar 

S.E. Kahn, B. Zinman, J.M. Lachin, S.M. Haffner, W.H. Herman, R.R. Holman et al. Rosiglitazone-associated fractures in type 2 diabetes. Diab. Care 31(5), 845–851 (2008)

Article  CAS  Google Scholar 

P. Vestergaard, L. Rejnmark, L. Mosekilde, Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48(7), 1292–1299 (2005)

Article  PubMed  CAS  Google Scholar 

H.M. Colhoun, S.J. Livingstone, H.C. Looker, A.D. Morris, S.H. Wild, R.S. Lindsay et al. Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia 55(11), 2929–2937 (2012)

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wang Y., Yu L., Ye Z., Lin R., Sun A.R., Liu L., et al. Association of metformin use with fracture risk in type 2 diabetes: a systematic review and meta-analysis of observational studies. Front. Endocrinol. 11, 13 (2013). https://www.frontiersin.org/articles/10.3389/fendo.2022.1038603/full

M.J. Nanjan, M. Mohammed, B.R. Prashantha Kumar, M.J.N. Chandrasekar, Thiazolidinediones as antidiabetic agents: a critical review. Bioorg. Chem. 77, 548–567 (2018)

Article  PubMed  CAS  Google Scholar 

A.A. Ali, R.S. Weinstein, S.A. Stewart, A.M. Parfitt, S.C. Manolagas, R.L. Jilka, Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146(3), 1226–1235 (2005)

Article  PubMed  CAS  Google Scholar 

G.L. Rubin, Y. Zhao, A.M. Kalus, E.R. Simpson, Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res. 60(6), 1604–1608 (2000)

PubMed  CAS  Google Scholar 

D. Seto-Young, M. Paliou, J. Schlosser, D. Avtanski, A. Park, P. Patel et al. Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. J. Clin. Endocrinol. Metab. 90(11), 6099–6105 (2005)

Article  PubMed  CAS  Google Scholar 

Y.K. Loke, S. Singh, C.D. Furberg, Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. Can. Med Assoc. J. 180(1), 32–39 (2009)

Article  Google Scholar 

Z.-N. Zhu, Y.-F. Jiang, T. Ding, Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone 68, 115–123 (2014)

Article  PubMed  CAS  Google Scholar 

J. Ha, Y. Lim, M.K. Kim, H.-S. Kwon, K.-H. Song, S.H. Ko et al. Comparison of the effects of various antidiabetic medication on bone mineral density in patients with type 2 diabetes mellitus. Endocrinol. Metab. 36(4), 895–903 (2021)

Article  CAS  Google Scholar 

C.-L. Yen, C.-Y. Wu, C.-Y. Tsai, C.-C. Lee, Y.-J. Li, W.-S. Peng et al. Pioglitazone reduces cardiovascular events and dementia but increases bone fracture in elderly patients with type 2 diabetes mellitus: a national cohort study. Aging 15(7), 2721–2733 (2023)

Article  PubMed  PubMed Central  CAS  Google Scholar 

S.S. Johnston, C. Conner, M. Aagren, K. Ruiz, J. Bouchard, Association between hypoglycaemic events and fall‐related fractures in Medicare‐covered patients with type 2 diabetes. Diab. Obes. Metab. 14(7), 634–643 (2012)

Article  CAS  Google Scholar 

S.Α Paschou, A.D. Dede, P.G. Anagnostis, A. Vryonidou, D. Morganstein, D.G. Goulis, Type 2 diabetes and osteoporosis: a guide to optimal management. J. Clin. Endocrinol. Metab. 102(10), 3621–3634 (2017)

Article  PubMed  Google Scholar 

Z. Zhang, Y. Cao, Y. Tao, EM, J. Tang, Y. Liu et al. Sulfonylurea and fracture risk in patients with type 2 diabetes mellitus: a meta‐analysis. Diab. Res Clin. Pr. 159, 107990 (2020)

Article  CAS  Google Scholar 

C.R. Dormuth, G. Carney, B. Carleton, K. Bassett, J.M. Wright, Thiazolidinediones and fractures in men and women. Arch. Intern. Med. 169(15), 1395 (2009)

Article  PubMed  CAS  Google Scholar 

I. Kanazawa, T. Yamaguchi, M. Yamamoto, T. Sugimoto, Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus. J. Bone Min. Metab. 28(5), 554–560 (2010)

Article  CAS  Google Scholar 

Sohi Y.H., Golestani A., Panahi G., Tabatabaei-Malazy O., Khalagi K., Fahimfar N., et al. The association between anti-diabetic agents and osteoporosis, sarcopenia, and osteosarcopenia among Iranian older adults; Bushehr Elderly Health (BEH) program. DARU J. Pharm. Sci. (2023). https://link.springer.com/10.1007/s40199-023-00497-5

M. Monami, B. Cresci, A. Colombini, L. Pala, D. Balzi, F. Gori et al. Bone fractures and hypoglycemic treatment in type 2 diabetic patients. Diab. Care 31(2), 199–203 (2008)